2 results
Approved WMOCompleted
To determine altered brain-activity during the performance of a sensitive perceptual-motor task following the administration of the antihistamine dexchlorpeniramine 4mg.
Approved WMOPending
Part 1 (Dose Escalation) - to identify the recommended Phase 2 dose(s) and schedule(s) to be safe for JNJ-79635322. Part 2 (Dose Expansion) is to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s).